10x Genomics is trading at $72.43, down 10.19%, with no confirmed company-specific catalyst identified for the October 12 decline. - Latest surfaced company news was an October 7 collaboration announcement, which was not linked to the drop. - Recent quarterly results showed revenue down year over year despite raised full-year guidance; available reporting does not establish those results as the cause of this session’s move. - Major indexes were mixed and moved less than 0.5% in the supplied market context, so broad-market direction does not clearly explain the decline.